Latest Headlines

Latest Headlines

Illumina strikes sequencing deal with England's 100K Genome Project

When Illumina unveiled its HiSeq X Ten in January, the alignment between its capabilities and the needs of England's 100K Genome Project were clear. The project aims to sequence 100,000 genomes by 2017 for around $160 million, figures that only look achievable using the massive output and relatively low costs of the HiSeq X Ten. This week the tie-up became official.

Illumina working to turn smartphones into 'molecular stethoscopes'

While Apple, Google and Samsung are all trying to persuade people to use their mobile technology to create personal health hubs, Illumina plans to take the concept further still. The genomic giant is working to turn smartphones into "molecular stethoscopes" that could change how patients interact with the healthcare and research ecosystems.

Chinese upstart takes aim at Illumina with homegrown DNA sequencer

Having seen off Roche's 454 Life Sciences and established a big lead over its remaining rivals, Illumina now faces a new challenger for the DNA sequencing market.

Illumina launches innovative sequencing technology for genetic prescreening of embryos

Fresh on the heels of promising Q1 numbers, Illumina is launching its innovative sequencing technology for the preimplantation genetic screening (PGS) of embryos.

Ariosa faces new patent pushback from rival Illumina

Ariosa Diagnostics is facing legal pushback after filing plans for a $60 million IPO to support development of its prenatal genetic test. Illumina filed a new patent infringement suit against the company, seeking an injunction against the company's noninvasive diagnostic tool.  

Wellcome Trust order helps Illumina blast past HiSeq X Ten sale forecasts

When Illumina unveiled its $1,000 genome machine, there were a few doubts about how many organizations had a big enough sequencing pipeline to justify buying the equipment. Now a purchase by the Wellcome Trust Sanger Institute has taken Illumina's order book up to 104 machines, almost double its original forecast.

Sequenom scores a blow against Illumina in prenatal Dx patent fight

Sequenom scored against Illumina's Verinata Health in a ruling at the U.S. Patent and Trademark Office involving noninvasive prenatal genetic diagnostic tech. Wasting no time, executives plan to use that decision as a weapon in an ongoing legal battle between the two California companies.

Illumina CEO sees bioinformatics as key to completing sequencing puzzle

The expansion of whole-genome sequencing into clinical care has intensified discussions about the limitations of the technology. Illumina CEO Jay Flatley this week acknowledged sequencing still has some weaknesses and identified what he sees as the solution--improved bioinformatics.

Illumina likely to start charging for BaseSpace storage and processing in 2014

Illumina released a pricing structure for its BaseSpace genomics cloud platform back in July 2012 but decided to hold off on actually charging users for the service. Since then, BaseSpace's user base has swelled to more than 12,000 people, with 2,000 of them logging on each week. Now the sequencing giant is readying to activate its payment model.

WuXi deepens its genomics might with Illumina, Pacific Biomarkers deals

Fresh off scoring U.S. certification for its genomics lab, China's WuXi PharmaTech is amping up its lab testing services, buying into Illumina's $1,000 genome technology and teaming up with Pacific Biomarkers to broaden its assay menu.